1 terminated, 1 withdrawn. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
Follow vocimagene amiretrorepvec: new trials by email Literature Review of vocimagene amiretrorepvec trials Research Report on vocimagene amiretrorepvec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma Extended Release Flucytosine, NovoTTF-100A Device, Quality-of-Life Assessment - Anaplastic Astrocytoma, Glioblastoma | Phase 2 / Phase 3 | Withdrawn | NRG Oncology | 2020-01-31 | 2026-05-07 | |
| The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Toca 511, Toca FC, Lomustine - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2 / Phase 3 | Terminated | Tocagen Inc. | 403 | 2015-11-30 | 2020-02-07 |
Astrocytoma (2) · Glioblastoma (2) · Oligodendroglioma (1) · Recurrence (1)
NRG Oncology (1) · Tocagen Inc. (1)
Canada (1) · Israel (1) · South Korea (1) · United States (1)
Manmeet S Ahluwalia (1) · Timothy Cloughesy, MD (1)
U10CA180868 (1)